Signal transduction protein TAB2

Details Signal transduction protein TAB2 Signal transduction protein TAB2

2006-12-04

2011-11-15

Salimi, Ali R. (Department: 1649)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

08058241

ABSTRACT:
A novel signal transducer TAB2 which acts as an adapter molecule of TRAF6 and TAK1 and mediates the activation of TAK1 in the signal transduction of IL-1 was isolated. TAB2 induced the activation of NF-κB and JNK by IL-1. The signal transduction by IL-1 was inhibited by inhibiting the signal transduction of TAB2 with the use of a dominant negative mutant of TAB2. A compound inhibiting the signal transduction in TAB2 is useful as an anti-inflammatory drug.

REFERENCES:
patent: 5470878 (1995-11-01), Michnick et al.
patent: 5576423 (1996-11-01), Aversa et al.
patent: 5837819 (1998-11-01), Matsuomoto et al.
patent: 5989862 (1999-11-01), Matsuomoto et al.
patent: 6140042 (2000-10-01), Matsuomoto et al.
patent: 2002/0119525 (2002-08-01), Matsuomoto et al.
patent: 0 803 571 (1997-10-01), None
patent: 10-4976 (1998-01-01), None
Mohler et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. Aug. 1, 1993;151(3):1548-61.
Cao et al., “TRAF6 is a signal transducer for interleukin-1,” Nature 383:443-446 (1996).
Hillier et al., “Generation and Analysis of 280,000 Human Expressed Sequence Tags,” Genome Research 6:807-828 (1996).
Nagase et al., “Prediction of the Coding Sequences of Unidentified Human Genes. XI. The Complete Sequences of 100 new cDNA Clones from Brain Which Code for Large Proteins in vitro,” DNA Research 5:277-286 (1998).
Ninomiya-Tsuji et al., “The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway,” Nature 398:252-256 (1999).
Ohara et al. EMBL Accession No. AB018276 (1998).
Poustka et al. EMBL Accession No. AL117407 (1999).
Sambrook et al., Molecular Cloning (1989).
Shibuya et al. “‘TAB1’ An Activator of the TAK1 MAPKKK in TGF-β Signal Transduction,” Science 272(5265):1179-1182 (1996).
Shibuya, “Functional role for TAB1-TAK1 in TGF-β signaling,” Seikagaku 71:1205-1212 (1999) (English translation).
Takaesu et al. “TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway,” Molecular Cell 5(4):649-658 (2000).
Takaesu et al., “Interleukin-1 (IL-1) Receptor-Associated Kinase Leads to Activation of TAK1 by Inducing TAB2 Translocation in the IL-1 Signaling Pathway,” Molecular and Cellular Biology 21:2475-2484 (2001).
Takaesu et al., “TAB2, a Novel Adaptor Protein, Mediates Activation of TAK1 MAPKKK by Linking TAK1 to TRAF6 in the IL-1 Signal Transduction Pathway,” Molecular Cell 5:649-658 (2000).
Tan et al., “Overcoming the inflammatory toxicity of cationic gene vectors,” Journal of Drug Targeting, 10(2):153-160 (2002).
Takaetsu et al., “Function of TAB2, a novel factor in IL-1 signaling pathway”, Program and Abstracts of the 21stAnnual Meeting of the Molecular Biology Society of Japan: Nov. 1998: 537 (#3P-461) (English translation included).
Sakurai et al., Biochem Biophys Res Comm. Feb. 13, 1998, vol. 243(2), pp. 545-549.
Fish & Richardson P.C., Preliminary Amendment in U.S. Appl. No. 10/151,569, filed Aug. 27, 2002 (6 pages).
Restriction Requirement in U.S. Appl. No. 10/151,569, mailed Aug. 5, 2003 (7 pages).
Fish & Richardson P.C., Response to Restriction Requirement in U.S. Appl. No. 10/151,569, mailed Aug. 5, 2003, filed Sep. 5, 2003 (1 page).
Office Action in U.S. Appl. No. 10/151,569, mailed Nov. 19, 2003 (17 pages).
Fish & Richardson P.C., Amendment in Reply to Office Action, in U.S. Appl. No. 10/151,569, mailed Nov. 19, 2003, filed May 19, 2004 (23 pages).
Final Office Action in U.S. Appl. No. 10/151,569, mailed Aug. 20, 2004 (8 pages).
Fish & Richardson P.C., Notice of Appeal and Amendment in Reply to Final Office Action, in U.S. Appl. No. 10/151,569, mailed Aug. 22, 2004, filed Feb. 22, 2005 (13 pages).
Notice of Allowance and Notice of Allowability in U.S. Appl. No. 10/151,569, mailed Mar. 18, 2005 (5 pages).
Fish & Richardson P.C., Request for Continued Examination in U.S. Appl. No. 10/151,569, filed Jun. 1, 2005 (1 page).
Notice of Allowance and Notice of Allowability in U.S. Appl. No. 10/151,569, mailed Jul. 14, 2006 (5 pages).
Fish & Richardson P.C., Response to Notice of Allowance, in U.S. Appl. No. 10/151,569, filed Oct. 13, 2006 (2 pages).
Fish & Richardson P.C., Request for Certificate of Correction in U.S. Appl. No. 10/151,569, filed Mar. 11, 2009 (2 pages).

Affiliated with

Also associated with

Rating

Signal transduction protein TAB2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Signal transduction protein TAB2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Signal transduction protein TAB2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4262811